Given that CD79a is a key component of the BcR, our findings are indicative of constitutive cell-intrinsic BcR signaling in CLL, which is more robust in the more clinically aggressive U-CLL subtype. This evidence concerns the gene CD79A and B-cell chronic lymphocytic leukemia.